BBOT Scores FDA Fast Track for BBO-11818: A New Targeted Therapy for KRAS-Mutant Pancreatic Cancer

BBOT receives U.S. FDA Fast Track Designation for BBO-11818, its pan-KRAS inhibitor for advanced KRAS-mutant pancreatic cancer. Phase 1 data expected H2 2026.